Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Myriad Genetic Laboratories, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of early stage non-small cell lung adenocarcinoma
Sub-population staging (IA, IB or IIA) as judged by the standard of practice at the investigational site
Resection of tumor within previous 2 months of enrollment
ECOG performance of 0-2
A minimum life expectancy of six months
You may not be if
Pre-operative radiation or chemotherapy for NSCLC
Post-operative radiation or chemotherapy for NSCLC
Enrollment in a separate clinical trial restricting treatment options
Unable to provide informed consent
Clareo Health | Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up
